[go: up one dir, main page]

DK1508047T3 - Fremgangsmåde til identifikation af immunoreaktive peptider - Google Patents

Fremgangsmåde til identifikation af immunoreaktive peptider

Info

Publication number
DK1508047T3
DK1508047T3 DK03735383T DK03735383T DK1508047T3 DK 1508047 T3 DK1508047 T3 DK 1508047T3 DK 03735383 T DK03735383 T DK 03735383T DK 03735383 T DK03735383 T DK 03735383T DK 1508047 T3 DK1508047 T3 DK 1508047T3
Authority
DK
Denmark
Prior art keywords
peptides
immunoreactive peptides
identifying
tumorous
identifying immunoreactive
Prior art date
Application number
DK03735383T
Other languages
English (en)
Inventor
Toni Weinschenk
Hans Georg Rammensee
Original Assignee
Immatics Biotechnologies Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immatics Biotechnologies Gmbh filed Critical Immatics Biotechnologies Gmbh
Application granted granted Critical
Publication of DK1508047T3 publication Critical patent/DK1508047T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C40COMBINATORIAL TECHNOLOGY
    • C40BCOMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
    • C40B30/00Methods of screening libraries
    • C40B30/04Methods of screening libraries by measuring the ability to specifically bind a target molecule, e.g. antibody-antigen binding, receptor-ligand binding
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0005Vertebrate antigens
    • A61K39/0011Cancer antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
DK03735383T 2002-05-29 2003-05-14 Fremgangsmåde til identifikation af immunoreaktive peptider DK1508047T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10225139A DE10225139A1 (de) 2002-05-29 2002-05-29 Verfahren zur Identifizierung von immunreaktiven Peptiden
PCT/EP2003/005038 WO2003100432A2 (de) 2002-05-29 2003-05-14 Verfahren zur identifizierung von immunreaktiven peptiden

Publications (1)

Publication Number Publication Date
DK1508047T3 true DK1508047T3 (da) 2008-10-20

Family

ID=29557590

Family Applications (1)

Application Number Title Priority Date Filing Date
DK03735383T DK1508047T3 (da) 2002-05-29 2003-05-14 Fremgangsmåde til identifikation af immunoreaktive peptider

Country Status (13)

Country Link
EP (1) EP1508047B1 (da)
JP (1) JP2005535299A (da)
AT (1) ATE403874T1 (da)
AU (1) AU2003236645B2 (da)
CA (1) CA2486738C (da)
CY (1) CY1108358T1 (da)
DE (2) DE10225139A1 (da)
DK (1) DK1508047T3 (da)
ES (1) ES2311710T3 (da)
IL (2) IL165398A0 (da)
PT (1) PT1508047E (da)
SI (1) SI1508047T1 (da)
WO (1) WO2003100432A2 (da)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1782070T3 (da) * 2004-06-17 2011-01-03 Mannkind Corp Tumorassocieret antigenprofiler i cancerdiagnostik og immunterapi
CA2651796A1 (en) * 2006-02-27 2007-09-07 Arizona Board Of Regents For And On Behalf Of Arizona State University Identification and use of novopeptides for the treatment of cancer
US9732131B2 (en) 2006-02-27 2017-08-15 Calviri, Inc. Identification and use of novopeptides for the treatment of cancer
US20090004213A1 (en) * 2007-03-26 2009-01-01 Immatics Biotechnologies Gmbh Combination therapy using active immunotherapy
GB201004551D0 (en) 2010-03-19 2010-05-05 Immatics Biotechnologies Gmbh NOvel immunotherapy against several tumors including gastrointestinal and gastric cancer
GB201019331D0 (en) * 2010-03-19 2010-12-29 Immatics Biotechnologies Gmbh Methods for the diagnosis and treatment of cancer based on AVL9
GB201004575D0 (en) * 2010-03-19 2010-05-05 Immatics Biotechnologies Gmbh Composition of tumor associated peptides and related anti cancer vaccine for the treatment of gastric cancer and other cancers
GB201006360D0 (en) 2010-04-16 2010-06-02 Immatics Biotechnologies Gmbh Method for differentially quantifying naturally processed HLA-restricted peptides for cancer, autoimmune and infectious diseases immunotherapy development
GB201423361D0 (en) 2014-12-30 2015-02-11 Immatics Biotechnologies Gmbh Method for the absolute Quantification of naturally processed HLA-Restricted cancer peptides
GB201604458D0 (en) 2016-03-16 2016-04-27 Immatics Biotechnologies Gmbh Peptides and combination of peptides for use in immunotherapy against cancers
WO2017194170A1 (en) 2016-05-13 2017-11-16 Biontech Rna Pharmaceuticals Gmbh Methods for predicting the usefulness of proteins or protein fragments for immunotherapy
DE102016123893A1 (de) 2016-12-08 2018-06-14 Immatics Biotechnologies Gmbh T-Zellrezeptoren mit verbesserter Bindung
EP4317432A3 (en) 2016-12-08 2024-04-17 Immatics Biotechnologies GmbH T cell receptors with improved pairing
US20200276285A1 (en) 2017-06-02 2020-09-03 Arizona Board Of Regents On Behalf Of Arizona State University A method to create personalized cancer vaccines
US12025615B2 (en) 2017-09-15 2024-07-02 Arizona Board Of Regents On Behalf Of Arizona State University Methods of classifying response to immunotherapy for cancer
DE102018122546B3 (de) 2018-09-14 2019-12-05 Immatics Biotechnologies Gmbh Verfahren zum Hochdurchsatz-Peptid-MHC-Affinitätsscreening für TCR-Liganden
DE102019114735A1 (de) * 2019-06-02 2020-12-03 PMCR GmbH HLA-Tumorantigenpeptiden der Klasse I und II zur Behandlung von Mamma-/Brustkarzinomen
DE102019121007A1 (de) 2019-08-02 2021-02-04 Immatics Biotechnologies Gmbh Antigenbindende Proteine, die spezifisch an MAGE-A binden
US20210032370A1 (en) 2019-08-02 2021-02-04 Immatics Biotechnologies Gmbh Recruiting agent further binding an mhc molecule
WO2021067550A1 (en) 2019-10-02 2021-04-08 Arizona Board Of Regents On Behalf Of Arizona State University Methods and compositions for identifying neoantigens for use in treating and preventing cancer
BR112023022765A2 (pt) 2021-05-05 2024-01-02 Immatics Biotechnologies Gmbh Proteínas de ligação ao antígeno que ligam especificamente o prame
EP4377330A1 (en) 2021-07-27 2024-06-05 Immatics Biotechnologies GmbH Antigen binding proteins specifically binding ct45
TW202506719A (zh) 2023-07-27 2025-02-16 德商艾瑪提克生物技術有限公司 針對mageb2之抗原結合蛋白
WO2025021979A1 (en) 2023-07-27 2025-01-30 Immatics Biotechnologies Gmbh Novel t cell receptors targeting melanoma-associated antigen (mage) b2 and immune therapy using the same
WO2025168848A1 (en) 2024-02-09 2025-08-14 IMMUNEO Therapeutics GmbH Hla tumor antigen polypeptides with delivering aiding capping peptides and pharmaceutical composition comprising the same
LU103243B1 (en) 2024-02-09 2025-08-11 PMCR GmbH Click chemistry hla tumor antigen polypeptides and pharmaceutical composition comprising the same
WO2025233420A1 (en) 2024-05-07 2025-11-13 Immatics Biotechnologies Gmbh Use of anti-cancer molecules
WO2025233431A1 (en) 2024-05-07 2025-11-13 Immatics Biotechnologies Gmbh Heteromeric proteins comprising three heteromerization improving substitution, production, combinations and applications thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6156317A (en) * 1996-11-12 2000-12-05 City Of Hope Immuno-reactive peptide CTL epitopes of human cytomegalovirus
DE10225144A1 (de) * 2002-05-29 2003-12-18 Immatics Biotechnologies Gmbh An MHC-Moleküle bindende Tumor-assoziierte Peptide

Also Published As

Publication number Publication date
CA2486738C (en) 2011-07-12
IL165398A0 (en) 2006-01-15
SI1508047T1 (sl) 2008-12-31
CA2486738A1 (en) 2003-12-04
DE10225139A1 (de) 2004-02-26
DE50310283D1 (de) 2008-09-18
ATE403874T1 (de) 2008-08-15
EP1508047A2 (de) 2005-02-23
AU2003236645B2 (en) 2009-06-18
ES2311710T3 (es) 2009-02-16
WO2003100432A3 (de) 2004-06-03
JP2005535299A (ja) 2005-11-24
IL165398A (en) 2013-04-30
CY1108358T1 (el) 2014-02-12
EP1508047B1 (de) 2008-08-06
WO2003100432A2 (de) 2003-12-04
AU2003236645A1 (en) 2003-12-12
PT1508047E (pt) 2008-10-02

Similar Documents

Publication Publication Date Title
DK1508047T3 (da) Fremgangsmåde til identifikation af immunoreaktive peptider
DE60139542D1 (de) Methoden zur herstellung humaner monoklonaler antikörper
ATE478381T1 (de) Verfahren zur bearbeitung von daten
EA199900162A1 (ru) Ингибиторы клеточной адгезии
CY1110295T1 (el) Trans-9,10-δεϋδροεποθιλονη c και d, αναλογα αυτων και μεθοδοι παρασκευης
DE60321256D1 (de) Spracherkennungssystem, Spracherkennungsverfahren und Programmprodukt
ATE517340T1 (de) Sätze gegen kurze epitope gerichteter digitaler antikörper sowie diese verwendende verfahren
PT1557462E (pt) Células de indução da aceitação de um transplante de origem monocítica e a sua preparação e utilização
EA200001129A3 (ru) Способ получения 4-карбоксиамино-2-замещенного-1,2,3,4-тетрагидрохинолина
DE60139466D1 (de) Behandlung von diabetes
NO20063304L (no) Fremgangsmate til a rense FSH
ES2061863T3 (es) Nuevas quinoliloxazol-2-onas utiles como inhibidores de proteina quinasa c.
WO2005027859A3 (en) Patch
PT1290160E (pt) Polipeptideos pellino humanos
WO2003073818A3 (en) Proteomic analysis of tumors for development of consultative report of therapeutic options
ES2502366T3 (es) Inducción de inmunidad tumoral por variantes de proteína de unión a folato
ATE527280T1 (de) Fluoreszentprotein und chromoprotein
WO2003073351A3 (en) Screening process
DK0914605T3 (da) Molekylemodel for VLA-4-inhibitorer
DK1488240T3 (da) Påvisning af specifikke nitrerede markører
EP1187336A3 (en) Compression in the presence of shared data
ATE500273T1 (de) Methoden zur analyse von antikörperdisulfidisomere
DE50210890D1 (de) Automatische identifikation und/oder verifikation linienhafter texturen wie fingerabdrücke
BRPI0506188A (pt) alternativas de análises em árvores de contexto
ATE437650T1 (de) Tyrosinasemutante und verfahren zur verwendung davon